Join Growin Stock Community!

Sionna therapeutics, inc.SION.US Overview

US StockHealthcare
(No presentation for SION)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SION AI Insights

SION Overall Performance

SION AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SION Recent Performance

-7.80%

Sionna therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SION PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SION Key Information

SION Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SION Profile

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

Price of SION

SION FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SION Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.27
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.27
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is SION's latest earnings report released?

    The most recent financial report for Sionna therapeutics, inc. (SION) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SION's short-term business performance and financial health. For the latest updates on SION's earnings releases, visit this page regularly.

  • How much debt does SION have?

    As of the end of the reporting period, Sionna therapeutics, inc. (SION) had total debt of 8.97M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SION have?

    At the end of the period, Sionna therapeutics, inc. (SION) held Total Cash and Cash Equivalents of 51.79M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SION's EPS continuing to grow?

    According to the past four quarterly reports, Sionna therapeutics, inc. (SION)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.46. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SION?

    Sionna therapeutics, inc. (SION)'s Free Cash Flow (FCF) for the period is -15.32M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 13.39% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.